Jonathan R Strosberg

Summary

Affiliation: University of South Florida
Country: USA

Publications

  1. ncbi Effective treatment of locally advanced endocrine tumors of the pancreas with chemoradiotherapy
    Jonathan Strosberg
    H Lee Moffitt Cancer Center and Research Institute, Tampa, Fla, USA
    Neuroendocrinology 85:216-20. 2007
  2. ncbi A review of the current clinical trials for gastroenteropancreatic neuroendocrine tumours
    Jonathan R Strosberg
    H Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612, USA
    Expert Opin Investig Drugs 16:219-24. 2007
  3. ncbi Metastatic carcinoid tumor to the ovary: a clinicopathologic analysis of seventeen cases
    Jonathan Strosberg
    H Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612, USA
    Gynecol Oncol 106:65-8. 2007
  4. ncbi Prognostic validity of the American Joint Committee on Cancer staging classification for midgut neuroendocrine tumors
    Jonathan R Strosberg
    Department of GI Oncology, H Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612, USA
    J Clin Oncol 31:420-5. 2013
  5. ncbi Incidental detection of pancreatic neuroendocrine tumors: an analysis of incidence and outcomes
    Asima Cheema
    Department of Gastrointestinal Oncology, H Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA
    Ann Surg Oncol 19:2932-6. 2012
  6. ncbi Relapse-free survival in patients with nonmetastatic, surgically resected pancreatic neuroendocrine tumors: an analysis of the AJCC and ENETS staging classifications
    Jonathan R Strosberg
    Department of GI Oncology, H Lee Moffitt Cancer Center and Research Institute, Tampa, Florida 33612, USA
    Ann Surg 256:321-5. 2012
  7. ncbi First-line chemotherapy with capecitabine and temozolomide in patients with metastatic pancreatic endocrine carcinomas
    Jonathan R Strosberg
    Department of Gastrointestinal Oncology, H Lee Moffitt Cancer Center and Research Institute, Tampa, Florida 33612, USA
    Cancer 117:268-75. 2011
  8. ncbi Prognostic validity of a novel American Joint Committee on Cancer Staging Classification for pancreatic neuroendocrine tumors
    Jonathan R Strosberg
    Moffitt Cancer Center, 12902 Magnolia Dr, Tampa, FL, USA
    J Clin Oncol 29:3044-9. 2011
  9. ncbi A review of systemic and liver-directed therapies for metastatic neuroendocrine tumors of the gastroenteropancreatic tract
    Jonathan R Strosberg
    Department of Gastrointestinal Oncology, Moffitt Cancer Center, Tampa, FL 33612, USA
    Cancer Control 18:127-37. 2011
  10. ncbi Selective hepatic artery embolization for treatment of patients with metastatic carcinoid and pancreatic endocrine tumors
    Jonathan R Strosberg
    Hematology Oncology Program, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612-9497, USA
    Cancer Control 13:72-8. 2006

Detail Information

Publications21

  1. ncbi Effective treatment of locally advanced endocrine tumors of the pancreas with chemoradiotherapy
    Jonathan Strosberg
    H Lee Moffitt Cancer Center and Research Institute, Tampa, Fla, USA
    Neuroendocrinology 85:216-20. 2007
    ....
  2. ncbi A review of the current clinical trials for gastroenteropancreatic neuroendocrine tumours
    Jonathan R Strosberg
    H Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612, USA
    Expert Opin Investig Drugs 16:219-24. 2007
    ..This review summarises the present scope of clinical research in this field...
  3. ncbi Metastatic carcinoid tumor to the ovary: a clinicopathologic analysis of seventeen cases
    Jonathan Strosberg
    H Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612, USA
    Gynecol Oncol 106:65-8. 2007
    ..To evaluate the clinical behavior and histologic characteristics of metastatic carcinoid tumors to the ovary...
  4. ncbi Prognostic validity of the American Joint Committee on Cancer staging classification for midgut neuroendocrine tumors
    Jonathan R Strosberg
    Department of GI Oncology, H Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612, USA
    J Clin Oncol 31:420-5. 2013
    ..This classification has not been validated in a population consisting solely of midgut NETs. The purpose of this study was to test the prognostic validity of the classification in such a population...
  5. ncbi Incidental detection of pancreatic neuroendocrine tumors: an analysis of incidence and outcomes
    Asima Cheema
    Department of Gastrointestinal Oncology, H Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA
    Ann Surg Oncol 19:2932-6. 2012
    ..The frequency of incidental detection is unknown. It is also unclear whether patients with incidentally discovered, early-stage, asymptomatic tumors should be treated similarly to patients who present with tumor-related symptoms...
  6. ncbi Relapse-free survival in patients with nonmetastatic, surgically resected pancreatic neuroendocrine tumors: an analysis of the AJCC and ENETS staging classifications
    Jonathan R Strosberg
    Department of GI Oncology, H Lee Moffitt Cancer Center and Research Institute, Tampa, Florida 33612, USA
    Ann Surg 256:321-5. 2012
    ....
  7. ncbi First-line chemotherapy with capecitabine and temozolomide in patients with metastatic pancreatic endocrine carcinomas
    Jonathan R Strosberg
    Department of Gastrointestinal Oncology, H Lee Moffitt Cancer Center and Research Institute, Tampa, Florida 33612, USA
    Cancer 117:268-75. 2011
    ..The authors retrospectively evaluated the efficacy of capecitabine and temozolomide in 30 patients with metastatic pancreatic endocrine carcinomas to assess response rate, progression free survival (PFS), and overall survival (OS)...
  8. ncbi Prognostic validity of a novel American Joint Committee on Cancer Staging Classification for pancreatic neuroendocrine tumors
    Jonathan R Strosberg
    Moffitt Cancer Center, 12902 Magnolia Dr, Tampa, FL, USA
    J Clin Oncol 29:3044-9. 2011
    ..This classification has not yet been validated...
  9. ncbi A review of systemic and liver-directed therapies for metastatic neuroendocrine tumors of the gastroenteropancreatic tract
    Jonathan R Strosberg
    Department of Gastrointestinal Oncology, Moffitt Cancer Center, Tampa, FL 33612, USA
    Cancer Control 18:127-37. 2011
    ..New evidence demonstrates that these agents can also inhibit tumor growth. Other novel agents targeting the VEGF and mTOR pathways have recently been investigated in multicenter phase III studies...
  10. ncbi Selective hepatic artery embolization for treatment of patients with metastatic carcinoid and pancreatic endocrine tumors
    Jonathan R Strosberg
    Hematology Oncology Program, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612-9497, USA
    Cancer Control 13:72-8. 2006
    ..Morbidity is low when appropriate supportive care is provided. Hepatic artery embolization often results in regressions in patients with unresectable liver metastases from carcinoid or pancreatic endocrine tumors...
  11. ncbi A phase II study of RO4929097 in metastatic colorectal cancer
    Jonathan R Strosberg
    Dept of GI Oncology, H Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612, United States
    Eur J Cancer 48:997-1003. 2012
    ..RO4929097 is a selective inhibitor of γ-secretase. We tested the activity of RO4929097 in patients with metastatic, refractory colorectal cancer...
  12. ncbi Aggressive surgical resection in the management of pancreatic neuroendocrine tumors: when is it indicated?
    Pamela J Hodul
    Gastrointestinal Tumor Program, Departmentsof Surgery, H Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612, USA
    Cancer Control 15:314-21. 2008
    ..This paper discusses whether aggressive surgical intervention is indicated for PNETs and investigates what prognostic factors may assist in predicting which patients with invasive disease will benefit most from surgical intervention...
  13. ncbi Does Barrett's esophagus respond to chemoradiation therapy for adenocarcinoma of the esophagus?
    James S Barthel
    Department of Gastrointestinal Oncology, H Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, USA
    Gastrointest Endosc 71:235-40. 2010
    ..The response of esophageal adenocarcinoma to chemoradiation therapy is well described; however, the effect of chemoradiation on tumor-associated BE has not been specifically reported...
  14. ncbi Intermittent bowel obstruction due to a retained wireless capsule endoscope in a patient with a small bowel carcinoid tumour
    Jonathan R Strosberg
    H Lee Moffitt Cancer Center and Research Institute, 12902 Magnolia Drive, Tampa, FL 33612, USA
    Can J Gastroenterol 21:113-5. 2007
    ..To the authors' knowledge, this is the first case presentation of chronic, partial small bowel obstruction caused by unrecognized retention of a capsule endoscope...
  15. ncbi Multimodality approach for locally advanced esophageal cancer
    Khaldoun Almhanna
    Department of Gastrointestinal Oncology, H Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612, United States
    World J Gastroenterol 18:5679-87. 2012
    ..The role of adjuvant chemotherapy following curative resection is still unclear. External beam radiation therapy alone is considered palliative and is typically reserved for patients with a poor performance status...
  16. ncbi The NANETS consensus guidelines for the diagnosis and management of poorly differentiated (high-grade) extrapulmonary neuroendocrine carcinomas
    Jonathan R Strosberg
    Department of Gastrointestinal Oncology, H Lee Moffitt Cancer Center, Tampa, FL, USA
    Pancreas 39:799-800. 2010
    ..In patients with localized tumors undergoing surgical resection, adjuvant treatment (chemotherapy with or without radiation) is warranted in most cases...
  17. ncbi Multimodality management of a polyfunctional pancreatic endocrine carcinoma with markedly elevated serum vasoactive intestinal polypeptide and calcitonin levels
    Aejaz Nasir
    Department of Interdisciplinary Oncology, Neuroendocrine Cancer Research Group, H Lee Moffitt Cancer Center and Research Institute, University of South Florida, Tampa, FL 33612, USA
    Pancreas 36:309-13. 2008
    ..In summary, this is a unique case of metastatic VIP- and calcitonin-secreting pancreatic ECA with dramatic sustained clinical, biochemical, and objective tumor response to peptide receptor radionuclide therapy...
  18. ncbi Correlation between grade and prognosis in metastatic gastroenteropancreatic neuroendocrine tumors
    Jonathan Strosberg
    H Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612, USA
    Hum Pathol 40:1262-8. 2009
    ..Both mitotic rates and Ki-67 indexes are inversely associated with survival and can be analyzed independently for assignment of grade...
  19. ncbi Survival and prognostic factor analysis in patients with metastatic pancreatic endocrine carcinomas
    Jonathan Strosberg
    Department of Gastrointestinal Oncology, H Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612, USA
    Pancreas 38:255-8. 2009
    ..Our objective was to evaluate the stage-specific prognosis of patients with metastatic PECAs and to assess the impact of clinical and pathologic prognostic factors...
  20. ncbi Improved outcome with cytoreduction versus embolization for symptomatic hepatic metastases of carcinoid and neuroendocrine tumors
    Dana A Osborne
    Digestive Disorders Center, Tampa General Hospital, 1 Davis Island, Tampa, Florida 33601, USA
    Ann Surg Oncol 13:572-81. 2006
    ..Cytoreduction should be pursued whenever possible even if complete resection may not be achievable...
  21. ncbi Somatostatin receptor profiling in hepatic metastases from small intestinal and pancreatic neuroendocrine neoplasms: immunohistochemical approach with potential clinical utility
    Aejaz Nasir
    Gastrointestinal Tumor Program, Neuroendocrine Cancer Research, H Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612 9497, USA
    Cancer Control 13:52-60. 2006
    ..In patients with SSTR-negative ETs, the clinical response is generally absent or suboptimal, while nonfunctioning ETs with SSTR positivity show a variable response to such therapy...